Financial support has been secured for the continuation of the Phase 1 trial of MNA-001 and the validation of translational biomarkers related to TREM2 function in Alzheimer's disease. This funding will aid in conducting Phase 2 trials to evaluate the ability of MNA-001 to decelerate the progression of pathology and functional decline in patients. The validation of these translational biomarkers serves to validate Muna's distinctive approach in this research.